Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What fueled the previous growth in the zolgensma market?

The market size for Zolgensma has shown an XX (HCAGR) over recent years. This segment is projected to expand from a value of $XX million in 2024, escalating to $XX million in 2025. Consequently, this growth represents a compound annual growth rate (CAGR) of XX%. The notable growth observed during the past epoch is contributed by factors such as a rising incidence of spinal muscular atrophy, an upsurge in awareness surrounding genetic disorders, heightened healthcare spending, an increased frequency of genetic testing, and a surge in the number of health insurance policies.

What will be the zolgensma market size in the future?

The market size of Zolgensma is projected to experience a forecasted compound annual growth rate (FCAGR) of XX in the coming years, reaching a value of $XX million by 2029 with a compound annual growth rate (CAGR) of XX%. This projected growth during the forecast period is attributed to the rising interest in tailored medical treatments, escalation in worldwide healthcare expenditure, growth in the telemedicine sector, a heightened focus on treatments for uncommon diseases, and advancements in digital health technologies. The forecast period is also expected to see key trends such as advancements in gene therapy technologies, technological breakthroughs in production procedures, the emergence of new biomarkers, further advancements in digital health technologies and the development of intrathecal formulations.

Get your zolgensma market report here!

https://www.thebusinessresearchcompany.com/report/zolgensma-global-market-report

What main drivers are fueling expansion in the zolgensma market?

The zolgensma market is predicted to grow due to the increasing amount of spinal muscular atrophy cases. This genetic disorder, also known as SMA, results in the degeneration of motor neurons in the spinal cord, causing progressive muscle weakness and atrophy. Primarily affecting infants and young children, the disease can lead to severe physical disabilities and life-threatening complications. Advances in genetic testing and newborn screening programs have led to more accurate diagnoses, thus identifying more SMA cases that might have previously been overlooked. Zolgensma provides a functional copy of the SMN1 gene to SMA patients, addressing the genetic root of the disease. This gene replacement helps restore the production of the survival motor neuron (SMN) protein, crucial for muscle strength and motor function, thereby improving motor skills and survival rates in affected children. For example, the National Health Service England stated in August 2023 that approximately 70 children are born with SMA each year in the UK. Furthermore, as of November 2022, 118 out of 161 SMA Type 1 patients were over the age of two and did not require permanent ventilatory support. Hence, the continual rise in spinal muscular atrophy cases is fueling the zolgensma market’s growth.

What key areas define the segmentation of the global zolgensma market?

The zolgensma market covered in this report is segmented –

1) By Indication: Spinal Muscular Atrophy (SMA) Type 1; Spinal Muscular Atrophy (SMA) Type 2; Spinal Muscular Atrophy (SMA) Type 3; Pre-symptomatic Spinal Muscular Atrophy (SMA)

2) By Age Group: Pediatric (Infants And Children); Adults

3) By Distribution Channel: Hospitals; Specialty Clinics; Pharmacies

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20373&type=smp

Who are the dominant players expanding their reach in the zolgensma market?

Major companies operating in the zolgensma market are Novartis AG

How are evolving market trends shaping zolgensma Strategies?

Strategic investments for augmenting production capabilities, geographical outreach, and accelerating innovative gene therapy research and development efforts define the major trend in the Zolgensma market. These investments don’t just bolster production capacity to meet escalating demand but also encourage advancements in gene therapy research. They further facilitate the expansion of geographic markets, streamline supply chain operations, and promote collaborative efforts for better awareness and treatment accessibility. For example, in April 2022, the US Food and Drug Administration permitted Novartis AG, a pharmaceutical corporation based in Switzerland, commercial licensing for its dedicated multi-product gene therapy manufacturing facility in Durham, North Carolina. This approval allows this 170,000 sq. ft. facility to engage in the production, testing, and commercial release of Zolgensma, and to produce gene therapy products for current and future clinical trials. It will also be instrumental in the fabrication of gene therapy commodities for both existing and forthcoming clinical trials.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20373

Which regions are emerging as leaders in the zolgensma market?

North America was the largest region in the zolgensma market in 2024. The regions covered in the zolgensma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Gene Therapy Global Market Report 2025

https://thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Global Alpha Mannosidosis Opportunities And Strategies Global Market Report 2025

https://thebusinessresearchcompany.com/report/alpha-mannosidosis-global-market

Global Cell And Gene Therapy Opportunities And Strategies Global Market Report 2025

https://thebusinessresearchcompany.com/report/cell-and-gene-therapy-market-

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: